Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25528906 | 0.86 | HPGD (0.53) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL227336 | 0.86 | HPGD (0.55) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL4402979 | 0.84 | HPGD (0.54) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL16142409 | 0.84 | HPGD (0.54) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL741520 | 0.83 | EPHX1 (0.54) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27912903 | 0.83 | HPGD (0.53) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL23104490 | 0.81 | HPGD (0.51) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL1106553 | 0.81 | HPGD (0.51) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL21551199 | 0.81 | HPGD (0.51) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL21551201 | 0.81 | HPGD (0.51) | HPGDRECQLEPHX1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664027-B1 | SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2009-12-30 | — | — | EP | claimed |
| JP-4392348-B2 | — | — | 2009-12-24 | — | — | JP | claimed |
| JP-4338974-B2 | — | — | 2009-10-07 | — | — | JP | claimed |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | claimed |
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | claimed |
| EP-1664023-B1 | SUSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2008-08-13 | — | — | EP | claimed |
| US-7390820-B2 | Substituted quinolinone derivatives and methods of use | AMGEN INC. (US) | 2008-06-24 | — | — | US | claimed |
| EP-1562933-B1 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | AMGEN INC (US) | 2008-03-19 | — | — | EP | claimed |
| US-7320992-B2 | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use | AMGEN INC. (US) | 2008-01-22 | — | — | US | claimed |
| US-7307088-B2 | Substituted anthranilic amide derivatives and methods of use | AMGEN INC. (US) | 2007-12-11 | — | — | US | claimed |
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | claimed |
| EP-1358161-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Amgen Inc. (US) | 2003-11-05 | — | — | EP | claimed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | claimed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | claimed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | claimed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | claimed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | claimed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | claimed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | claimed |
| WO-2002055501-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMGEN INC (US) | 2002-07-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | HPGD 84/4885RECQL 1070/4885EPHX1 288/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | HPGD 116/4885RECQL 1469/4885EPHX1 386/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | HPGD 99/4885RECQL 1307/4885EPHX1 222/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | HPGD 116/4885RECQL 1469/4885EPHX1 386/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | HPGD 99/4885RECQL 1307/4885EPHX1 222/4885 |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | FLT1, FLT4, NAT1 | HPGD 250/4885RECQL 696/4885EPHX1 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.